NCT06541262View on ClinicalTrials.gov

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

November 1, 2030

Study Completion Date

November 1, 2035

Conditions
Neuroblastoma RecurrentEwing's Sarcoma RecurrentOsteosarcoma RecurrentRhabdomyosarcoma RecurrentLiposarcoma Recurrent
Interventions
DRUG

Silmitasertib

Capsules

DRUG

Irinotecan

IV

DRUG

Temozolomide

Oral

DRUG

Vincristine

IV

Trial Locations (5)

17033

RECRUITING

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey

32806

RECRUITING

Arnold Palmer Hospital for Children, Orlando

33614

RECRUITING

St. Joseph's Children's Hospital, Tampa

64108

RECRUITING

Children's Mercy Hospitals and Clinics, Kansas City

96813

RECRUITING

Kapiolani Medical Center for Women and Children, Honolulu

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER